Compare INBS & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBS | ICCM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.3M |
| IPO Year | 2019 | 2013 |
| Metric | INBS | ICCM |
|---|---|---|
| Price | $2.35 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 95.8K | 94.1K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,980,484.00 | N/A |
| Revenue This Year | $778.48 | $139.51 |
| Revenue Next Year | N/A | $75.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.13 |
| 52 Week High | $24.90 | $9.54 |
| Indicator | INBS | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 37.78 |
| Support Level | $2.26 | $2.12 |
| Resistance Level | $2.45 | $3.59 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 24.50 | 13.53 |
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.